(Tiper Stock Exchange) – Philogenan Italian-Swiss biotech company listed on Euronext Milan, closed the first quarter 2023 with a positive net financial position of Euro 66,731 thousand, compared to a net financial position, still positive, of Euro 70,438 thousand as at 31 December 2022, showing a decrease of 5.3%.
“The group closes the first quarter of 2023 with a net financial position of 66.7 million, testifying to a efficient and targeted resource management“, commented theCEO Dario Neri.
“The Nidlegy Phase III trial in melanoma it reached 87 of the 95 events necessary for the read-out of the study – he explained – We expect to reach the 95th event in the second half of 2023. We remind you that an event corresponds to a tumor recurrence or the death of a patient. We are extremely excited about the data with Nidlegy in high-risk and basal cell carcinoma, which the group will increase its investment in over the coming months to accelerate patient enrollment.”
“THE Fibromun registration trials “Following the completion of the Phase I of the Fibromun study in recurrent glioblastoma in Switzerland, the trial will begin randomized Phase II in a few weeks,” he added.